Navigation Links
PharmAthene Reports Third Quarter 2011 Financial and Operating Results
Date:11/9/2011

ANNAPOLIS, Md., Nov. 9, 2011 /PRNewswire/ --

Third Quarter Highlights

  • Recognized total revenue of $5.3 million
  • Awarded $5.7 million contract from Department of Defense (DoD) for nerve agent medical countermeasure program
  • Delaware Court of Chancery awarded PharmAthene 50% net profit split on worldwide sales of ST-246 and related products once SIGA realizes the first $40 million in net profits
  • Completed 1500L commercial scale-up and first cGMP manufacturing run for SparVax™

  • PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported financial and operating results for the third quarter ended September 30, 2011.

    Eric I. Richman, President and Chief Executive Officer, commented, "The third quarter was a transformative one for PharmAthene.  As we reported in September, after nearly 5 years of litigation against SIGA Technologies, the Delaware Court of Chancery issued a ruling in favor of PharmAthene.  The court awarded PharmAthene the right to receive 50% of the net profits from sales of SIGA's ST-246 smallpox antiviral therapeutic and related products over 10 years, once SIGA receives the first $40 million in net profits.

    "Based on SIGA's public disclosures, deliveries of this product to the U.S. government could occur as early as late summer 2012 or early 2013.  We believe this represents a major potential revenue stream for PharmAthene that should allow us to accelerate near-term profitability and create enhanced value for PharmAthene shareholders.  

    "Since the ruling, SIGA has subsequently filed a motion for re-argument, which is pending before the Court.  If the Court denies the motion, the parties will have 20 days from that date to submit a proposed form of final judgment, followin
    '/>"/>

    SOURCE PharmAthene, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. PharmAthene Progresses Second Generation rPA Anthrax Vaccine
    2. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
    3. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
    4. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
    5. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
    6. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
    7. PharmAthene Completes $6.5 Million Registered Direct Offering
    8. PharmAthene Reports First Quarter 2011 Financial and Operating Results
    9. PharmAthene to Host Year-End 2010 Earnings Conference Call and Webcast on Monday, March 28, 2011
    10. PharmAthene Strengthens Scientific Leadership and Program Management for Future Growth
    11. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/4/2015)... , March 4, 2015 Vegalab announced ... in August of last year. As part of the ... Bon Koo continuing his role as CEO for ... of Vegalab S.A., will work alongside Koo and oversee ... - http://photos.prnewswire.com/prnh/20150303/179218 Koo founded ...
    (Date:3/3/2015)... - Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a ... target the underlying mechanisms of cancer, today reported financial ... 31, 2014. Effective July 17, 2014, the ... to December 31. As a result of that change, ... quarter and the seven months ended December 31, 2014, ...
    (Date:3/3/2015)... Mar. 03, 2015 Research and Markets ... "Gene Therapy Market, 2015 - 2025" report ... Market, 2015-2025" report provides an extensive study on the ... has been carried out in this field for over ... (four available in Asian markets; one approved in the ...
    (Date:3/3/2015)... Crown Bioscience, Inc., a leading global drug ... Life Science division specializing in in vivo and in ... first products released include in vivo grade human and ... released in vivo grade monoclonal antibodies against PD-L1 and ... science portfolio with additional antibody products as well as ...
    Breaking Biology Technology:Korean Government Program Supports Vegalab's Research and Development 2Korean Government Program Supports Vegalab's Research and Development 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7Crown Bioscience Launches Life Science Product Catalog 2
    ... BETHESDA, Md., Oct. 24, 2011 Spherix Incorporated ... in biotechnology for therapy in diabetes, metabolic syndrome ... consulting services to food, supplement, biotechnology and pharmaceutical ... of D-tagatose and SPX-106) reduced dyslipidemia in new ...
    ... DLVR Therapeutics Inc. ("DLVR") - a privately-held ... based on its proprietary high density lipoprotein-like nanoparticle ... seed round investment bringing the total raised to ... Innovation joins the University Health Network (UHN) and ...
    ... 24, 2011 Marshall Edwards, Inc. (Nasdaq: MSHL ... novel therapeutics targeting cancer metabolism, announced today that Charles Baltic, ... has been appointed to its board of directors. The appointment ... six and the number of independent directors to five. ...
    Cached Biology Technology:Spherix Announces Results from New Preclinical Studies Showing SPX-106T Produces Significant Reductions in Cholesterol, Fat Deposition and Body Weight 2Spherix Announces Results from New Preclinical Studies Showing SPX-106T Produces Significant Reductions in Cholesterol, Fat Deposition and Body Weight 3Spherix Announces Results from New Preclinical Studies Showing SPX-106T Produces Significant Reductions in Cholesterol, Fat Deposition and Body Weight 4DLVR Therapeutics Inc. Raises Additional Capital Adding MaRS Innovation to Investor Base 2DLVR Therapeutics Inc. Raises Additional Capital Adding MaRS Innovation to Investor Base 3Marshall Edwards Appoints Healthcare Investment Banking Veteran Charles Baltic to Board of Directors 2Marshall Edwards Appoints Healthcare Investment Banking Veteran Charles Baltic to Board of Directors 3
    (Date:2/5/2015)... 2015  Marken is starting its 35 th ... a new marketing campaign to solidify its place as ... campaign focuses on First as a primary ... The first headline in the series, ... its client,s priorities. Marken recognizes the need to protect ...
    (Date:2/5/2015)... Jan. 28, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... RedChip Global Online CEO Conference on January 29 th ... Gino Pereira , CEO of NXT-ID will present and ... the Wocket smart wallet and its full suite of ...
    (Date:1/22/2015)... 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased ... State of Washington,s Department of Licensing, ... and central issuance system for driver,s licenses and identification cards ... planning and development will start in January 2015, with enrollment ...
    Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Valid USA Signs Contract For Washington Driver's License Issuance 2
    ... use knowledge about methane production by cold-weather microbes on ... similar, carbon-based microbes that could have evolved on Mars, ... three-year project, funded by a $2.4 million grant from ... program, will be led by biogeochemist Lisa Pratt. Her ...
    ... for informatics professionals, has weighed in on the Federal ... Office of the National Coordinator,s (ONC) call for comments ... set forth by the U.S. Congress and the Administration. ... MD, summarizes AMIA,s comments simply: "Because health IT ...
    ... 11 May 2011 - Two new research studies published ... in brain development that emerge as vulnerable individuals develop ... with a deletion of a small section of chromosome ... of abnormalities in the structure of the heart and ...
    Cached Biology News:NASA project eyes climate change in Greenland -- with a third eye on Mars 2NASA project eyes climate change in Greenland -- with a third eye on Mars 3AMIA identifies areas to strengthen Federal health IT strategic plan 2Brain development goes off track as vulnerable individuals develop schizophrenia 2
    ... quadrupole 1200L sets the new standard ... - incorporating the latest technologies and ... chromatography analytical needs. The Atmospheric ... Transmission Quadrupole Analyzer provide superior selectivity ...
    Human beta IG-H3 MAb (Clone 348506) Keywords: BIGH3, betaIG-H3 Protein Family: Extracellular Matrix Molecules...
    Catalase (Control)...
    Human RELT/TNFRSF19L Affinity Purified Polyclonal Ab...
    Biology Products: